Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XXX-Lean is a multi-ingredient dietary supplement marketed for weight loss and thermogenesis. It is primarily known for being the subject of regulatory seizures by Health Canada due to its inclusion of unauthorized and potentially hazardous substances. The formulation typically contains MaHuang extract (standardized for ephedrine), Guarana extract (standardized for caffeine), and L-carnitine. Ephedrine acts as a sympathomimetic agent that stimulates the central nervous system and increases metabolic rate, while caffeine provides additional stimulation and enhances the thermogenic effect. This combination, often referred to as an 'ECA stack' (though carnitine replaces aspirin here), is intended to promote fat loss but is associated with significant cardiovascular risks, including increased heart rate and blood pressure. The product has been manufactured by entities such as UK Pharma and EU Pharma, often through contract manufacturers like Professional Botanicals Inc.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on XXX-Lean.